RPRX Royalty Pharma Corp: Net earnings per share for the last four quarters

Patent loss risks and regulatory pressure contrast with stable cash flows from oncology blockbusters. Annual EPS (TTM) growth statistics visualize this trend, where -12.00 forms the current metric value. The financial stability of Royalty Pharma plc (RPRX) is based on a diversified portfolio of rights to high-demand drugs, while the company does not engage in its own drug manufacturing.
royaltypharma.com - analytical breakdowns and key metrics (RPRX)

EPS (TTM) growth measures the dynamics of net income per share, reflecting the efficiency of profit generation relative to the cost of capital. This metric serves as a stress-testing tool for business resilience against changes in resource costs. By analyzing the annual EPS (TTM) growth statistics, an investor assesses the real return on assets. For Royalty Pharma plc (RPRX), this is confirmed by the steady release of patented drugs by partners without the costs of maintaining its own manufacturing plants.